Different Cardiotoxicity of Palbociclib and Ribociclib in ... - PubMed
WEBOur results show that ribociclib, but not palbociclib, could act by down-regulating the expression of KCNH2 (encoding for potassium channel hERG) and up-regulating SCN5A and SNTA1 (encoding for sodium channels Nav1.5 and syntrophin-α1, respectively), three genes associated with long QT syndrome.
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast …
WEBSep 16, 2019 · Our results show that ribociclib, but not palbociclib, could act by down-regulating the expression of KCNH2 (encoding for potassium channel hERG) and up-regulating SCN5A and SNTA1 (encoding for sodium channels Nav1.5 and syntrophin-α1, respectively), three genes associated with long QT syndrome.
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone ...
WEBMay 31, 2023 · Background: RIB and PAL are CDK4/6 inhibitors with demonstrated efficacy in terms of progression-free survival (PFS) and similar tolerability in pts with HR+/HER2- ABC when combined with endocrine therapy (ET).
Ribociclib-Induced Cutaneous Adverse Events in Metastatic …
WEBJan 18, 2024 · Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs).
Initial real life experience with ribociclib in breast cancer: …
WEBMay 28, 2021 · Background: CDK4/6 inhibitors, such as ribociclib, are a new class of medications that are used in combination with hormonal therapy to treat advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The primary objective of this study is to evaluate the tolerance and cardiac …
WEBOct 8, 2016 · Ribociclib (LEE011) is an orally bioavailable, selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cell-cycle progression
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2 …
WEBApr 12, 2022 · Ribociclib was FDA-approved in combination with letrozole based on a Phase III study in which 668 postmenopausal women with HR+, HER2-negative recurrent or metastatic BC were treated with first-line letrozole with or without ribociclib.
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2 …
WEBApr 12, 2022 · Ribociclib has all the characteristics of an innovative drug that can change the clinical practice and most BC patients’ prognosis. This review highlights patient selection and particular settings in which medical oncologists urgently await advances in treatment.
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · The absolute benefit with ribociclib plus an NSAI at 3 years was 3.3 percentage points. These results support the use of ribociclib in the treatment of HR-positive, HER2-negative early breast...
FDA expands ribociclib indication in HR-positive, HER2-negative ...
WEBOn July 18, 2018, the Food and Drug Administration expanded the indication for ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in combination with an aromatase inhibitor for...